Carcinoma, Ovarian Epithelial: all 1,619 studies
Page 2 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian CancerNot yet recruitingNCT06315270
- A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian CancerRecruitingNCT06308406Phase 1/2
- Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T CellsRecruitingNCT06305299Phase 1
- Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian CancerRecruitingNCT06292286Not applicable
- A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryRecruitingNCT06279104
- Administration of Hyperthermic Intraperitoneal Chemotherapy in the General WardNot yet recruitingNCT06277947Not applicable
- Tumor Microenvironment in Ovarian CancerRecruitingNCT06272240
- Exercise and Nutrition Intervention in Ovarian CancerRecruitingNCT06250686Not applicable
- Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )RecruitingNCT06249308
- Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid TumorsRecruitingNCT06243185Phase 2
- Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer PatientsRecruitingNCT06236958
- Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian CancerRecruitingNCT06232122Not applicable
- Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).RecruitingNCT06229522
- SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive SurgeryRecruitingNCT06223763
- Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine ConstitutionRecruitingNCT06222008
- Evaluation of Amino Acid Metabolism Changes in Ovarian CancerRecruitingNCT06216496Not applicable
- A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian CancerNot yet recruitingNCT06211023Phase 2/3
- Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian CancerNot yet recruitingNCT06188455Phase 3
- Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer PatientsRecruitingNCT06182917
- Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
- Transforming Ovarian Cancer Diagnostic PathwaysRecruitingNCT06129968
- Shanghai Ovarian Cancer and Family Care ProjectRecruitingNCT06118307
- Systems Oncology Approach to Optimize Ovarian Cancer TreatmentRecruitingNCT06117384
- The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer PatientsNot yet recruitingNCT06102707Not applicable
- Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective StudyRecruitingNCT06085456
- Patients Derived Organoids in Ovarian CancerRecruitingNCT06085404Not applicable
- Unravelling Tumour Biology In Ovarian Cancer With Precision ImagingRecruitingNCT06084195Not applicable
- Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT06081595Phase 2
- Investigating Participation Patterns Among Recurrent Ovarian Cancer PatientsNot yet recruitingNCT06070285
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
- SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian CancerNot yet recruitingNCT06055348Phase 1/2
- A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of NiraparibRecruitingNCT06037213
- PRO for Fighting FT in Ovarian CancerRecruitingNCT06032975
- Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary TreatmentsRecruitingNCT06025045
- A Cohort Establishment Study of Total Management of Ovarian CancerRecruitingNCT06018935
- IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerRecruitingNCT06014528Phase 2
- HS-20089 in Patients With Ovarian Cancer and Endometrial CancerRecruitingNCT06014190Phase 2
- A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT06010667
- The Immune Landscape of Epithelial Ovarian CancerRecruitingNCT05984875
- Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian CancerRecruitingNCT05983276Phase 2
- Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian CancerNot yet recruitingNCT05976932
- Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian CancerNot yet recruitingNCT05965141Phase 1/2
- Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerRecruitingNCT05961124Phase 2
- MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian CancerRecruitingNCT05960630Not applicable
- Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian CancerRecruitingNCT05937620Not applicable
- The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian CancerNot yet recruitingNCT05931055
- The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of ActionRecruitingNCT05926336Phase 4
- Plasmodium Immunotherapy for Advanced Ovarian CancerNot yet recruitingNCT05924776Phase 2/3
- Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian CancerNot yet recruitingNCT05921149Not applicable
- Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian CancerRecruitingNCT05874115
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2
- ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian CancerRecruitingNCT05862740Not applicable
- Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial CarcinomaRecruitingNCT05856643Early Phase 1
- Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer RecurrenceRecruitingNCT05856409
- Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)RecruitingNCT05855941
- Improved Diagnosis of Ovarian CancerRecruitingNCT05842629
- Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)RecruitingNCT05827523Phase 3
- A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian CancerRecruitingNCT05824247
- FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian CancerRecruitingNCT05810701Not applicable
- Appraising Medical Trial Experiences of Ovarian Cancer PatientsNot yet recruitingNCT05801796
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian CancerRecruitingNCT05801783Early Phase 1
- ctDNA Methylation for Detecting Ovarian CancerRecruitingNCT05801276
- ctDNA Methylation for Epithelial Ovarian CancerRecruitingNCT05801263
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian CancerNot yet recruitingNCT05794659Phase 2
- NEOadjuvant Dendritic Cell Vaccination for Ovarian CancerRecruitingNCT05773859Phase 1/2
- Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian CancerNot yet recruitingNCT05749211Not applicable
- Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian CancerRecruitingNCT05737303Phase 3
- CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsRecruitingNCT05733000Phase 2
- Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor MaintenanceRecruitingNCT05704621Phase 2
- Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening ToolsRecruitingNCT05697601
- Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian CancerRecruitingNCT05684731Phase 1
- A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian CancerNot yet recruitingNCT05641506Phase 2
- Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 TrialRecruitingNCT05607329Not applicable
- Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)RecruitingNCT05606692Phase 4
- Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)RecruitingNCT05601700Phase 3
- Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerNot yet recruitingNCT05597527Phase 2
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingNCT05585281Phase 2
- Efficacy and Adverse Effects of Niraparib in Ovarian Cancer.Not yet recruitingNCT05583799
- Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPiRecruitingNCT05551208Phase 2
- AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
- Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
- Intraperitoneal Lidocaine in Ovarian Cancer SurgeryNot yet recruitingNCT05450055Not applicable
- Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian CancerRecruitingNCT05446545
- Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian CancerRecruitingNCT05444270Not applicable
- Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian CancerRecruitingNCT05431530
- AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian CancerRecruitingNCT05430906Phase 2
- A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)RecruitingNCT05429970Not applicable
- New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer RecurrenceRecruitingNCT05410028
- Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian CancerRecruitingNCT05410015
- HRD and Resistance to PAPPi in EOC PatientsRecruitingNCT05310370
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable
- Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian CancerRecruitingNCT05284552Phase 2
- Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian CancerRecruitingNCT05272462Phase 2
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3
- A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omicsRecruitingNCT05251883
- Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian CancerRecruitingNCT05236686Not applicable
- Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian CancerRecruitingNCT05211557Phase 1/2
- A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian CancerRecruitingNCT05206890
- Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerRecruitingNCT05200260Phase 2
- PARP Inhibitor Oral Maintenance in Low-Risk Ovarian CancerNot yet recruitingNCT05187208Phase 4